drugset / Trial / NCT01586169

Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination

NCT01586169

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the triple co administration of albendazole, ivermectin and azithromycine is as safe as the current treatment scheme that consists to treat with albendazole plus ivermectin together and a week later to treat with azithromycin in areas co endemic for lymphatic filariasis and trachoma.

Timeline

Start
2010-02
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Albendazole Small molecule 400 mg
Subject Azithromycin Small molecule
Subject Ivermectin Small molecule